venBio Partners LLC — 13F Holdings & Portfolio
CIK 1776382 · latest 13F-HR filed 2026-08-14
venBio Partners LLC manages $519.4M in 13F-reported U.S. long-equity assets across 7 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are PHVS (30.92%), PBLS (27.75%), ALMS (24.53%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 2 new positions and exited 1; 3 existing positions rose in reported value and 1 fell.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
Long-equity book
Distinct positions
Filed 2026-08-14
vs 2026-03-31
Portfolio charts
Latest quarter's book, what changed, and how the portfolio has evolved across filings.
| Name | Title / Status | Ownership | Type |
|---|
Quarter-over-quarter changes
Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.
Top Adds (vs prior quarter)
- PHARVARIS N V$29.5M +22.5%
- ALUMIS INC$27.7M +27.7%
- HARMONY BIOSCIENCES HLDGS IN$3.5M +25.5%
venBio Partners LLC Holdings (2026-06-30)
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | PHARVARIS N V | PHVS | N69605108 | $160.6M | 30.92% | 4,643,430 | SH |
| 2 | PARABILIS MEDICINES INC | PBLS | 698955101 | $144.1M | 27.75% | 5,266,697 | SH |
| 3 | ALUMIS INC | ALMS | 022307102 | $127.4M | 24.53% | 4,528,408 | SH |
| 4 | ACHIEVE LIFE SCIENCE INC | ACHV | 004468500 | $38.6M | 7.44% | 5,914,720 | SH |
| 5 | ALX ONCOLOGY HLDGS INC | ALXO | 00166B105 | $26.7M | 5.14% | 12,884,638 | SH |
| 6 | HARMONY BIOSCIENCES HLDGS IN | HRMY | 413197104 | $17.2M | 3.31% | 472,194 | SH |
| 7 | LYELL IMMUNOPHARMA INC | LYEL | 55083R203 | $4.7M | 0.91% | 337,697 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-14 | $519.4M | 7 | 0000905148-26-003741 |
| 2026-03-31 | 2026-05-15 | $280.6M | 6 | 0000905148-26-002409 |
| 2025-12-31 | 2026-02-17 | $216.3M | 6 | 0000905148-26-000841 |
| 2025-09-30 | 2025-11-14 | $176.4M | 6 | 0000905148-25-004034 |
SAN FRANCISCO, CA 94158